Dobi Medical on track with breast cancer imager
This article was originally published in Clinica
Dobi Medical International says it is on track with plans to submit a US marketing application for its angiogenesis-based breast cancer imaging system next summer. The Mahwah, New Jersey firm has begun a clinical trial which will be the subject of the fifth and final module of its premarket approval (PMA) application with the FDA for its flagship product, the ComfortScan system. Patient enrolment has now started at several leading medical centres, with additional sites expected to begin enrolling patients in early 2005.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.